Embecta to buy Owen Mumford for up to $201M

Group 1 - Embecta has agreed to acquire Owen Mumford Holdings for up to 150 million pounds ($201 million), which includes an upfront payment of 100 million pounds and potential performance payments of up to 50 million pounds based on sales of Owen Mumford's Aidaptus auto-injector [7] - The acquisition is expected to enhance Embecta's revenue growth trajectory and facilitate its transition into a broader medical supplies firm, according to Embecta CEO Devdatt Kurdikar [7] - Owen Mumford reported revenue of 69.4 million pounds in its 2025 fiscal year, while Embecta reported $1.08 billion in revenue last year [4] Group 2 - The acquisition will allow Embecta to serve patients in various markets, including obesity, diabetes, autoimmune diseases, and anaphylaxis [3] - Embecta anticipates that the purchase will contribute to revenue growth in its fiscal 2027 and be immaterial to adjusted operating income that year, becoming accretive thereafter [5] - Owen Mumford's business is divided between medical devices and pharmaceutical services, with the latter expected to grow more rapidly due to the anticipated adoption of the Aidaptus auto-injector platform [4]